Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317354 · ClinicalTrials.gov registry record
People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 13
- Enrollment target
NCT02317354: Completed study, sponsored by National Eye Institute (NEI).
NCT02317354 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02317354 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
Background: -X-linked retinoschisis (XLRS) is an inherited eye condition. Researchers want to learn more about how people with XLRS choose to take part in research studies. They hope to find ways to help other people make decisions about joining early phase trials Objective: -To learn more about how people think and feel about taking part in early phase research. Eligibility: -Adults age 18 or older with diagnosed XLRS. They must be eligible to be screened for a Phase I/II ocular gene transfer clinical trial. Design: * Participants will be screened for the XLRS gene transfer study. They will be interviewed: * Eligible participants who join the study - before the gene transfer procedure, then 3 months and 12 months after it. * Eligible participants who do not join the study - after their screening visit and 3 months and 12 months later. \<TAB\>- Participants who are screened but ineligible - after their screening visit. \<TAB\>- Participants who choose not to be screened - at the time they make the decision and 1 year later. * Interviews will ask for the participants thoughts about the clinical trial and why they chose to take part or not. The interviews will be recorded. * On the day of interview 1, participants will fill out a survey about their mood and personality. * On the days of interviews 2 and 3, participants will fill out a survey about their mood. * Interviews may be done in person or by phone. Surveys can be done online or through the mail. Or they can be done in person at the NIH Clinical Center.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-12-13 |
| Est. Completion | 2017-11-20 |
What the finished NCT02317354 record still lists
NCT02317354 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02317354 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02317354 about?
NCT02317354 is a clinical study titled "People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial". Background: -X-linked retinoschisis (XLRS) is an inherited eye condition. Researchers want to learn more about how people with XLRS choose to take part in research studies. They hope to find ways to help other people make decisions about joining early phase trials Objective: -To learn more about ...
What is the current status of trial NCT02317354?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2014-12-13. Estimated completion is 2017-11-20.
Who is sponsoring clinical trial NCT02317354?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI